What does immune medicine business — goodwill mean?

This metric represents the intangible asset value recorded by the Immune Medicine Business segment following an acquisition, reflecting the premium paid over the fair value of net identifiable assets. It serves as an indicator of the segment's historical growth through acquisitions and potential future impairment risks.

Adaptive Biotechnologies ADPT Immune Medicine Business — Goodwill

Other segment segments

Mrd Business

$96.4M0.0%

Similar metrics at other companies

ASHLife Sciences — Goodwill

$462M-42.8%

JNJPharmaceutical — Goodwill (Note 3)

$14.81B+35.8%

MIRMedical Segment — Goodwill

$634M0.0%

AMRXAffordable Medicines — Goodwill

$158.02M-2.3%

VOYAInvestment Management Segment — Goodwill

$286M0.0%

EXLSHealthcare and Life Sciences — Goodwill

$189.57M0.0%

Other financials

Income statement

See full

Revenue$70.9M+35.1%

Gross profit$52.2M+47.1%

Operating income-$19.2M+35.1%

Net income-$20.0M+32.9%

EPS (diluted)-$0.13+35.0%

Balance sheet

See full

Cash & equivalents$77.6M+53.2%

Total debt$208.2M-5.6%

Total equity$216.3M+13.6%

Total assets$505.9M-1.0%

Cash flow

See full

Operating cash flow-$9.5M+66.5%

CapEx$796.0K-36.8%

Free cash flow-$10.3M+65.3%

Valuation

See full

Market cap$2.76B+93.6%

Enterprise value$2.89B+78.0%

P/S9.3×+1.8×

Profitability

See full

Gross margin75.3%+12.7pp

Operating margin-15.8%-7.0pp

Net margin-16.8%-7.3pp

FCF margin-10.5%-4.6pp

Returns & leverage

See full

Return on equity-24.4%-9.2pp

Debt / equity1×-0.2×

Current ratio3.4×+0.4×

Where this comes from

Reported directly by Adaptive Biotechnologies in its filing.

Tagged under the XBRL concept us-gaap:Goodwill.

The official record: Adaptive Biotechnologies’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Adaptive Biotechnologies's immune medicine business — goodwill.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Adaptive Biotechnologies's immune medicine business — goodwill?: Adaptive Biotechnologies (ADPT) reported immune medicine business — goodwill of $22.6M in Q4 2025.
What does immune medicine business — goodwill mean?: This metric represents the intangible asset value recorded by the Immune Medicine Business segment following an acquisition, reflecting the premium paid over the fair value of net identifiable assets. It serves as an indicator of the segment's historical growth through acquisitions and potential future impairment risks.